FerringUSA.com | Contact Us
Understanding OA of the Knee     Causes     Disease Progression     Treatment Options

How does OA of the knee progress?
In the healthy knee joint, a smooth, cushiony substance called cartilage covers the ends of the bones and protects them from rubbing against each other. There is a space between the ends of the bones that holds a fluid called synovial fluid. Synovial fluid surrounds, lubricates, and protects the joint.

In the early stages of osteoarthritis (OA) of the knee, tiny cracks and pits may begin to form in the cartilage as its surface begins to break down.

Over time, large sections of cartilage may lose flexibility and begin to wear down. Cartilage in poor condition is more likely to be damaged by daily wear and tear or injury. Bone spurs may form on the edges of the bones. At the same time, the synovial fluid begins to break down, losing its ability to cushion and lubricate the joint.

Eventually, sections of cartilage may completely wear away, leaving the ends of the bones unprotected, rubbing painfully against each other. Also, tiny pieces of cartilage or bone may float in the joint space, causing further damage and pain.

There is good news. OA of the knee is manageable, especially if detected in the early stages of the disease. That’s why it’s important to contact your doctor if you have pain or stiffness in your knee. Only your doctor can diagnose OA of the knee, and together you and your doctor can choose a treatment that’s right for you.

Privacy Policy | Legal Disclaimer

Click here to receive announcements and additional information about EUFLEXXA.
Click here to request press materials.
Important Treatment Considerations

EUFLEXXA™ (1% sodium hyaluronate) is indicated for the treatment of knee pain due to osteoarthritis (OA). It is used in people who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy.

EUFLEXXA should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site.

In a randomized, double-blind, multicenter clinical trial, the only adverse event reported with EUFLEXXA at an incidence greater than 5% was arthralgia (joint pain) (8.75%). Temporary knee pain and swelling may occur after injection with EUFLEXXA.

The safety and effectiveness of injecting EUFLEXXA into the knee together with other injectable medications or into joints other than the knee have not been studied. The safety and effectiveness of treatment cycles of fewer than 3 injections or of repeated treatment cycles with EUFLEXXA have not been established. Strict aseptic technique must be followed to avoid joint infection.

Prescribing Information for Physicians
Important Information for People With OA of the Knee